MCC
OCUL icon

Money Concepts Capital’s Ocular Therapeutix OCUL Stock Holding History

Money Concepts Capital’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,000
Closed -$2.81K – 2083
2022
Q4 		$2.81K Buy
+1,000
New +$3.31K ﹤0.01% 2578

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Money Concepts Capital's OCUL Position: Q1 2023 in Review

Money Concepts Capital sold out of Ocular Therapeutix (OCUL) in Q1 2023, closing a stake of 1,000 shares — an estimated $2.81K sold.

Money Concepts Capital first reported a position in OCUL in Q4 2022 and held it in 1 quarter. The position peaked at $2.81K in Q4 2022. 127 funds tracked by Wall St. Rank hold OCUL as of Q1 2023.

  • Money Concepts Capital reported no remaining Ocular Therapeutix position as of Q1 2023 after selling out during the quarter.
  • Money Concepts Capital sold 1,000 Ocular Therapeutix shares in Q1 2023, an estimated $2.81K.
  • Money Concepts Capital first reported a position in Ocular Therapeutix in Q4 2022 and held it in 1 quarter.
  • Money Concepts Capital's Ocular Therapeutix position peaked at $2.81K in Q4 2022.
  • 127 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2023.

Based on Money Concepts Capital's 13F filing for Q1 2023, filed 1 May 2023.